Barrett's esophagus secondary prevention

Barrett's Esophagus Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Barrett's Esophagus from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Endoscopic Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Barrett's esophagus secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Barrett's esophagus secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Barrett's esophagus secondary prevention
CDC on Barrett's esophagus secondary prevention
Barrett's esophagus secondary prevention in the news
Blogs on Barrett's esophagus secondary prevention
Directions to Hospitals TreatingBarrett's esophagus
Risk calculators and risk factors for Barrett's esophagus secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Amresh Kumar MD [2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary prevention

Recommendations:

• Therapy with medications effective to treat GERD symptoms and to heal reflux esophagitis is strongly recommended.

• Do not attempt to eliminate acid exposure of the esophagus

1. Use proton pump inhibitors in doses greater than once daily. There is no evidence that higher doses produce a risk reduction in cancer.
2. Titrate proton pump inhibitors dose by esophageal pH monitoring.
3. Anti-reflux surgery. This is not more effective than medical therpay.

Risks and benefits of long-term PPI therapy should be discussed with the patients.

• Do not use aspirin to prevent esophageal adenocarcinoma in the absence of other indications (e.g. cardiovascular risk factors). Although evidence suggests NSAIDs may decrease the incidence of esophageal cancer, it is not clear if benefits outweight the risks of using this medications.

Secondary Prevention

• There are no established measures for the secondary prevention of [disease name].

OR

• Effective measures for the secondary prevention of [disease name] include:
  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]